Last reviewed · How we verify
PD-1 and PD-L1 inhibitor — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
PD-1 and PD-L1 inhibitor (PD-1 and PD-L1 inhibitor) — Tianjin Medical University Cancer Institute and Hospital.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| PD-1 and PD-L1 inhibitor TARGET | PD-1 and PD-L1 inhibitor | Tianjin Medical University Cancer Institute and Hospital | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- PD-1 and PD-L1 inhibitor CI watch — RSS
- PD-1 and PD-L1 inhibitor CI watch — Atom
- PD-1 and PD-L1 inhibitor CI watch — JSON
- PD-1 and PD-L1 inhibitor alone — RSS
Cite this brief
Drug Landscape (2026). PD-1 and PD-L1 inhibitor — Competitive Intelligence Brief. https://druglandscape.com/ci/pd-1-and-pd-l1-inhibitor. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab